In 2022, Jordan has seen successful applications of Jafron's hemoperfusion devices in two patients. That means the further improvement of hemoperfusion technology, and its wider applications may save lives for many, which is for the good of the Jordanian healthcare sector.

Background: For the People, to the People

According to the World Bank, Jordan is ranked first in the MENA region as the best healthcare service provider and a top destination for medical tourism. Physicians tend to be Western-educated and well-regarded. They can offer the world's leading medical treatment in industries like cardiology and cardiovascular surgery, kidney transplantation, and oncology. 

The common treatments in blood purification include peritoneal dialysis and hemodialysis, continuous venovenous hemofiltration(CVVH), and plasmapheresis. Perfusion technique was a stranger to them. However, as another alternative to blood-purification therapy, it can also be employed in critical care, life support for organ failures, and the redress of metabolic and immune disorders.

With a common wish to offer patients more choices and reduce the burden in the local healthcare industry, the Jafron group and Jordanian local partners have endeavored to facilitate the clinical application of the hemoperfusion technique in nephrology, hepatology, and critical care. 

The first application was on June 15th, 2022, at Al Kindi Hospital for a patient suffering from septic shock. The patient's conditions were well controlled after three times of hemoperfusion treatments with the use of HA380 disposable hemoperfusion cartridges. 

About a month after the initial success, on July 19th, 2022, the first Double Plasma Molecular Adsorption System (DPMAS) treatment, with the help of Jafron Future F20 hemoadsorption equipment, was delivered to a patient suffering from a hepatic coma. The treatment went well, which can be seen by the patient's bettering physical indicators. From now on, a new chapter of Jordanian hepatopathy treatment has just opened up. 

Education: Foster Mutual Trust

Double plasma molecular adsorption system (DPMAS) is one of the promising non-biological liver support systems that have been extensively investigated in acute, chronic liver failure from hepatitis B viral. DPMAS circuit consists of BS330 (bilirubin adsorber) and HA330 (Cytokines adsorber). Thus, DPMAS can remove various cytokines.

The first application provides experts and professors access to know its performance. On August 9th, 2022, Jafron and the local partners held the first academic symposium about the DPMAS's clinical application, both online and offline. Attendees include Pro. Smadi at DRMS, several hepatologists, and healthcare workers. 

Professor Zhu Juanjuan, from the Affiliated Hospital of Guizhou Medical University Infection Division, introduced the artificial liver support technique, especially DPMAS, and shared some clinical cases, talking about basic information about the technique, for example, the contraindications and the enrollment criteria of the patients. The symposium also offered a platform for presenting the Future F20 hemoadsorption equipment and DPMAS-related hemoperfusion cartridges and machine. 

Conclusion

The successful applications and symposiums enable further education for the DPMAS technique, which Jafron team and local partners believe will benefit the people here. At last, Jafron will promote multilateral cooperation with the local hospitals, allowing the widest range of people to get to know Jafron and its hemoperfusion technology. 

Reference

[1] Jordan's healthcare industry, available at:

https://www.trade.gov/country-commercial-guides/jordan-healthcare

[2] Employment of blood purification, available at:

https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-purification

[3] What is DPMAS, available at: 

https://clinicaltrials.gov/ct2/show/NCT05030571